斯托克斯位移
荧光团
荧光
光热治疗
生物相容性
荧光寿命成像显微镜
材料科学
分子成像
光动力疗法
临床前影像学
纳米技术
体内
生物物理学
化学
光学
物理
生物技术
生物
有机化学
冶金
作者
Mengyao Li,Weiping Zhou,Wei Zhou,Chang Liu,Shuang Song,Wenzhao Han,Ying Li,Di He,Cong Yu
出处
期刊:ACS Biomaterials Science & Engineering
[American Chemical Society]
日期:2024-06-10
卷期号:10 (7): 4541-4551
标识
DOI:10.1021/acsbiomaterials.4c00496
摘要
NIR-II imaging-guided phototherapy is an attractive, yet challenging, tumor treatment strategy. By monitoring the accumulation of phototherapy reagents at the tumor site through imaging and determining the appropriate therapy window, the therapeutic effect could be significantly improved. Probes with NIR-II (1000–1700 nm) fluorescence emission and a large Stokes shift hold great promise for fluorescence imaging with deep penetration, minimized self-quenching, and high spatiotemporal resolution. However, due to the lack of a suitable molecular framework, the design of a simple small-molecule dye with a large Stokes shift and NIR-II fluorescence emission has rarely been reported. Herein, we prepare an asymmetric D−π–A type NIR-II fluorescence probe (TBy). The probe is incapsulated in an amphiphilic polymer and modified with a fibronectin targeting peptide CREKA, which could recognize the fibrin–fibronectin complex overexpressed in multiple malignant tumors. The nanoparticles thus constructed (TByC-NPs) have maximum fluorescence emission at 1037 nm with a large Stokes shift of 426 nm, which is the largest Stokes shift among organic NIR-II fluorescent dyes reported in the literature. The TByC-NPs exhibit a good NIR-II imaging performance, active tumor targeting, and good photothermal and photodynamic capabilities. In vitro and in vivo studies verify that the TByC nanoplatform shows outstanding biocompatibility for NIR-II imaging-guided phototherapy and provides an excellent antitumor effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI